•  
  •  
 

Yih-Dih Cheng, School of Pharmacy, China Medical University, Taichung 406040, Taiwan
Chi‑Cheng Lu, Department of Sport Performance, National Taiwan University of Sport, Taichung 404401, Taiwan
Yuan-Man Hsu, Department of Biological Science and Technology, College of Life Sciences, China Medical University, Taichung, Taiwan 406040, Taiwan
Fuu-Jen Tsai, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 404333, Taiwan
Da-Tian Bau, Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404333, Taiwan
Shih-Chang Tsai, Department of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan
Ching-Chang Cheng, Laboratory Animal Service Center, China Medical University, Taichung 404333, Taiwan
Jen-Jyh Lin, Division of Cardiology, Department of Medicine, China Medical University Hospital, Taichung 404327, Taiwan
Yuang-Yu Huang, Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan
Yu-Ning Juan, Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan
Yu-Jen Chiu, Division of Plastic and Reconstructive Surgery, Department of Surgery, Taipei Veteran General Hospital, Taipei 112201, Taiwan
Sheng-Chu Kuo, School of Pharmacy, China Medical University, Taichung 406040, Taiwan
Jai-Sing Yang, Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan
Lii-Tzu Wu, Department of Microbiology, School of Medicine, China Medical University, Taichung 404333, TaiwanFollow

Abstract

COVID-19 pandemic has been a global outbreak of coronavirus (SARS-CoV-2 virus) since 2019. Taiwan Chingguan Yihau (NRICM101) is the first traditional Chinese medicine (TCM) classic herbal formula and is widely used for COVID-19 patients in Taiwan and more than 50 nations. This study is to investigate in silico target fishing for the components of NRICM101 and to explore whether NRICM101 inhibits cytokines-induced normal human lung cell injury in vitro. Our results showed that network prediction of NRICM101 by a high throughput target screening platform showed that NRICM101 has multiple functions that may affect cytokine regulation to prevent human lung cell injury. In addition, NRICM101 revealed protective effects against TNF-α/IL-1β-induced normal human lung HEL 299 cell injury through JNK and p38MAPK kinase signaling. Next-generation sequencing (NGS) analysis of NRICM101 on TNF-α/IL-1β-injured HEL 299 cells indicated that inflammatory pathway, cell movement of macrophages, cellular infiltration by macrophages, and Th1/Th2 immuno-regulation pathways were included. Thus, NRICM101 is a therapeutic agent, and it can improve COVID-19 syndrome to confer beneficial effects through multiple targeting and multiple mechanisms.

Additional Files
Supplementary Figure S1.pptx (1280 kB)

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS